Karyopharm Phase 3 SENTRY Trial Results Selected for ASCO 2026 Late-Breaking Presentation in Myelofibrosis

Key Takeaways

• Karyopharm’s Phase 3 SENTRY trial earned a coveted late-breaking oral presentation at ASCO 2026, indicating significant clinical results
• The randomized, double-blind, placebo-controlled trial targets myelofibrosis, a rare blood cancer with limited treatment options
• Results will be presented May 29-June 2, 2026 in Chicago, potentially advancing new treatment options for myelofibrosis patients

---

NEWTON, Mass. – Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced today that its Phase 3 SENTRY trial results have been selected for a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 to June 2 in Chicago.

Significance of Late-Breaking Selection

The selection for a late-breaking presentation represents a significant achievement, as ASCO reserves these slots for studies with practice-changing potential or unexpected breakthrough results. This designation suggests the SENTRY trial may have met its primary endpoints or demonstrated clinically meaningful outcomes for myelofibrosis patients.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

About the SENTRY Trial

The Phase 3 SENTRY trial is a randomized, double-blind, placebo-controlled study evaluating Karyopharm’s investigational therapy in myelofibrosis patients. Myelofibrosis is a rare bone marrow cancer that disrupts normal blood cell production, affecting approximately 1 in 500,000 people annually.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Implications

Karyopharm, a commercial-stage pharmaceutical company specializing in novel cancer therapies, has been developing treatments that target nuclear export mechanisms. The company’s lead compound, selinexor, is already approved for multiple myeloma and diffuse large B-cell lymphoma.

The myelofibrosis treatment landscape remains challenging, with current therapies primarily focused on symptom management rather than disease modification. A successful SENTRY trial could represent a significant advancement for patients facing this difficult-to-treat malignancy.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

What’s Next

The presentation at ASCO 2026 will provide the first public disclosure of detailed trial results. Healthcare professionals, investors, and patient advocacy groups will closely monitor the data for potential regulatory filing implications and treatment paradigm shifts in myelofibrosis care.

---

Frequently Asked Questions

What does this ASCO selection mean for myelofibrosis patients?

The late-breaking presentation suggests promising trial results that could lead to a new treatment option for myelofibrosis, a rare blood cancer with limited current therapies.

When will the SENTRY trial results be available?

The results will be presented during the oral presentation at ASCO 2026, taking place May 29 to June 2, 2026 in Chicago.

How significant is a late-breaking presentation at ASCO?

Late-breaking presentations are reserved for studies with practice-changing potential or unexpected breakthrough results, indicating the SENTRY trial likely achieved meaningful clinical outcomes.

Related coverage

• Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026
• OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation
• KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)